Genenta Science S.p.A., a clinical-stage biotechnology company pioneering hematopoietic stem progenitor cell immuno-gene therapy for solid tumors - led by its flagship product candidate, Temferon™ - rang the closing bell at the NASDAQ Stock Exchange. Growth Capital acted as financial advisor to Genenta’s management team.
